Top Machine Learning Companies in Boston, MA (158)

Product Line Growth: Product rollouts across 2025–2026—such as the LLM‑ready API, new Figure Extraction in Extract, Adaptive/Deterministic Retrieval, and a major Kensho Link upgrade—signal widening capabilities and scope. Evidence points to an expanded feature set that connects trusted S&P Global datasets to LLMs and agentic workflows.

Market Expansion: API call volume acceleration (e.g., a February-to-March 2026 doubling) and Kensho Link’s coverage increase to 70+ million entities indicate a larger addressable footprint and rising utilization. Ecosystem integrations with platforms like Anthropic’s Claude and Cohere further extend distribution beyond native S&P interfaces.

Future-Ready Strategy: S&P Global’s positioning of Kensho as its embedded AI engine—reinforced by the 2026 reorganization creating “Kensho Data & Platforms” and references to sustained AI investment—underscores a plan geared to scale AI‑powered products and workflows. Materials consistently highlight Kensho’s central role in enabling AI experiences across S&P’s portfolio.

Strong Revenue Growth: Q2 2026 total net revenue rose 4% sequentially to $15.9 billion. Integration of Discover and Brex contributed to higher non‑interest income and broader payments capabilities.

Profitability: Q2 2026 net income reached $3.0 billion, up from $2.2 billion in Q1 2026, alongside a net interest margin of 8.01%. Management also cited strong credit performance, including a $662 million reserve release.

Market Expansion: Acquisition‑driven scale is broadening reach, with the Discover deal (closed May 18, 2025) and Brex (closed April 7, 2026) adding network and corporate card/spend‑management capabilities. Balance‑sheet growth continued in Q2 2026 as period‑end loans rose 2% to $457.2 billion and total assets reached $673.8 billion.

Investor Backing & Capital Strength: Recent capital raises include a $56.1M Series C in July 2024 and additional growth financing in March 2026 to expand product, sales, and customer success. These transactions point to strong investor support and resources to scale.

Product Line Growth: New and enhanced offerings such as the Group Health Risk Management Life Cycle (Sept 2025) and workers’ comp tools like ClaimVector and a 2026 triage solution indicate active product development. This expansion supports broader use cases across underwriting and claims.

Strong Revenue Growth: Company communications highlight double‑digit year‑over‑year growth since founding and well over 100% growth exiting 2022, with a later 50% YoY increase in platform volume. These signals suggest ongoing commercial momentum.

Strong Revenue Growth: ARR is described as rising from over $300M in 2025 to over $400M by mid-2026, alongside large-scale telemetry usage that signals expanding adoption. This trajectory indicates sustained top-line expansion through 2026.

Innovation-Driven Growth: AI-led capabilities such as Edwin AI are portrayed as a meaningful driver of bookings with rapid recurring revenue momentum, and the company is advancing an “Autonomous IT” roadmap. Continued AI feature launches through 2026 point to product-led expansion.

Investor Backing & Capital Strength: An $800M financing in late 2024 at around a multi‑billion valuation provides resources to accelerate platform expansion, acquisitions, and entry into new markets. This capital base supports ongoing scaling initiatives.

Strong Revenue Growth: Global ARR is described as growing almost 40% year over year, with a 55% increase in customers spending over $100K annually. Enterprise adoption includes over 25 Fortune 500 and nearly 50 Fortune Global 2000 organizations.

Market Expansion: International momentum includes 178% growth in APAC and 52% in EMEA, alongside Japan ARR roughly 2.4x from 2021 to 2025. A new Technical Account Manager service launch in Japan further signals localized investment.

Product Line Growth: The launch of “Active Coverage” in April 2026 and continuous additions across mobile, performance, API, and integrations (e.g., Playwright, Atlassian Rovo) expand the platform’s surface area. Rapid uptake of GenAI features such as Assertions and Autoheal underscores widening product utilization.

Investor Backing & Capital Strength: A $200M Series C in July 2024 at a reported $1B valuation provides material resources for product expansion and scaling. Active hiring across engineering, product, sales, and government affairs aligns with investment-fueled growth plans.

Market Expansion: U.S. Customs and Border Protection executed a formal two-year contract to test the platform in 2025. FedRAMP High authorization in February 2026 reduces procurement friction with federal agencies and regulated customers, positioning the company for broader rollout.

Product Line Growth: The July 2026 acquisition of Cervo AI enables an end-to-end, agentic customs brokerage workflow. Altana states this brings its logistics customer base to “8 of the 10 largest logistics providers,” indicating capability-driven expansion.

Strong Revenue Growth: Revenue is on a clear upward trajectory, with estimates rising from 2024 through 2025, leadership guiding to a substantially larger 2026, and a stated path toward $1B by 2028. This momentum is tied to increasing orders, expanding programs, and a growing mix of software and systems.

Investor Backing & Capital Strength: A multi‑billion‑dollar capital package closed in March 2026, including a $1.5B Series G at a $12.7B valuation plus additional preferred equity and a delayed‑draw facility. This financing depth provides runway to scale autonomy software, aircraft programs, and the Aechelon acquisition.

Market Expansion: Operations and sales expanded internationally with new contracts across allies including Romania, Japan, Greece, and Canada, while U.S. traction includes Air Force CCA autonomy selections and a Navy contract to further develop X‑BAT. Over time, these moves broaden geographic reach and platform adoption.

Strong Market Position & Advantage: The FAA selected ASI in June 2026 to help modernize the National Airspace System through a multi-year program that brings its Flyways AI into core ATC operations. This selection signals scale-up potential and long-term revenue visibility.

Customer Loyalty & Retention: Alaska Airlines adopted Flyways in 2021 and renewed the partnership in 2024, citing operational and fuel-efficiency benefits. Alaska’s subsequent reports and white papers describe ongoing, production use, indicating continued value delivery.

Market Expansion: Partnerships announced in 2026 with Joby Aviation for eVTOL integration and with National Grid to apply “operational AI” to the electric grid show movement into adjacent markets beyond traditional airlines. These moves broaden relevance across aviation and critical infrastructure.

Investor Backing & Capital Strength: Large late-stage financing and valuation momentum signal strong access to capital, including a $250M Series E and corroborated unicorn-scale valuations. Capital depth is further reinforced by indications of continued fundraising interest.

Strategic Partnerships: Embedded distribution with Zillow Rentals’ AI Assist, powered by EliseAI, is reported to drive higher renter engagement and application behavior. Such channel access expands reach and evidences measurable impact in real-world funnels.

Strong Revenue Growth: Company disclosures indicate surpassing $200M in ARR with continued acceleration from earlier milestones. Adoption signals across large operators align with sustained top-line expansion.

Strong Revenue Growth: Total revenue increased to $255.9M in 2025 with software up and drug‑discovery more than doubling, while operating expenses declined year over year. Early 2026 also showed momentum, with first‑half revenue modestly higher and Q2 posting year‑over‑year growth.

Strategic Partnerships: New and expanded agreements—such as Bristol Myers Squibb deploying Bunsen and a July 2026 discovery collaboration with Simcere—broaden platform use and collaboration optionality. The Lilly/Ajax transaction also validated the model and supported a higher 2026 drug‑discovery outlook.

Product Line Growth: The introduction of Bunsen, an agentic AI co‑scientist, expands the software portfolio and is being deployed at scale within BMS. This product push complements growth in ACV and broader platform adoption.

Market Expansion: Geographic footprint is widening with a 2024 Arlington office followed by a Seattle office in June 2025, explicitly framed as supporting continued growth. These additions position the company closer to key defense customers and talent pools on both coasts.

Innovation-Driven Growth: Recent prime awards across AI and autonomy—including a ~$98M Army STEAM IDIQ, a $48M Army OTA for UAS development, and DARPA’s Albatross—signal expanding technical scope and pipeline. Selection onto large multi‑award vehicles (e.g., IAC MAC Pool 2) further broadens access to work through 2025–2030.

Strong Hiring & Retention: Headcount indicators around 190+ employees and active multi‑site job postings into 2026 point to ongoing team growth. Repeated “Best Places to Work” recognition in Boston and Washington, D.C. aligns with effective talent attraction and retention.

Strong Revenue Growth: Revenue expanded rapidly, with FY2025 up 83% to about $1.27B and Q1/Q2 2026 up 36% and 22% year over year, respectively. Management also raised 2026 revenue guidance to approximately $1.595–$1.605B.

Diversified Revenue Streams: Both Diagnostics and Data & Applications are expanding, with Diagnostics up 34.7% in Q1 and 20% in Q2 2026 and Insights/data licensing up 36% in Q2 alongside about $200M in new licenses. Rising oncology test volumes (28–31% YoY) and accelerating MRD tests (~4,700 in Q4 2025 to ~9,000 in Q2 2026) reinforce multiple growth engines.

Profitability: The company achieved its first GAAP-profitable quarter in Q2 2026 (net income about $5.6M; Adjusted EBITDA ~$8.0M). Guidance points to further improvement in 2026, indicating progress toward sustained profitability.

Strong Market Position & Advantage: Repeated Leader placements in Gartner’s DEX Magic Quadrant (2024–2026) and Forrester’s 2024 EUEM Wave indicate durable competitive standing and sustained category momentum. These recognitions coincide with communications citing 1,200–1,500+ customers and 20M+ endpoints, underscoring broad enterprise adoption.

Product Line Growth: New offerings such as Adopt on Infinity (2025) and the Spark personal IT agent (2026), plus integrations like GoTo/Rescue and a government-focused AWS Marketplace listing, expand use cases and routes to market. The 2024 acquisition of AppLearn further broadened capabilities into digital adoption.

Investor Backing & Capital Strength: A late‑2025 majority investment by Vista Equity Partners at an approximately $3B valuation signals strong external confidence and provides resources for scaling. This step-up from the 2021 round supports continued product and go‑to‑market execution.

Strong Hiring & Retention: Hiring momentum, explicit “rapid growth” language on the careers page, and ongoing requisitions across Woburn/Boston, Arlington, Dayton, Melbourne, and San Diego point to expanding teams and stable retention. LinkedIn and careers postings indicate an active build-out across engineering and related functions.

Innovation-Driven Growth: Recent U.S. Navy awards, continued DARPA work through at least early 2026, and progress on multi‑phase programs (e.g., AIR and other DARPA initiatives) indicate expansion fueled by advanced R&D in AI/ML, sensing, cyber/EW, and mission software. Follow‑on options and modifications suggest programs are maturing rather than winding down.

Market Expansion: A five‑site U.S. footprint and active recruiting across these locations reflect scaled operations beyond a single hub. Participation on large DoD IDIQ vehicles and industry engagement (e.g., a CVPR 2026 workshop sponsorship) point to a widening market presence.

Resilient & Sustainable Growth: Growth is described as measured and predictable, with signals such as modest headcount expansion, sustained operating scale, and continued momentum rather than volatility.

Innovation-Driven Growth: Recent major releases across IRIS/IRIS for Health/Health Connect and new AI-focused offerings indicate ongoing R&D velocity that broadens capabilities and use cases.

Strong Market Position & Advantage: Repeated industry accolades for Shared Care Records/HIE and regional acute EHRs in 2026 point to durable competitive standing in core healthcare markets.

Investor Backing & Capital Strength: Strategic investment backing is positioned as growth-oriented support, with Vista Equity Partners described as making a strategic growth investment to help scale the platform.

Innovation-Driven Growth: Product expansion is framed around adding new capabilities, including the acquisition of Jebbit and embedding no-code interactive experiences to capture zero-/first-party data natively in the platform.

Strong Brand Reputation: Market recognition is portrayed as solid, with analyst placements like Strong Performer/Challenger in certain evaluations and references to award recognition and notable brand usage.

Market Expansion: Active hiring across multiple U.S. states in 2026 and an in‑force GSA Multiple Award Schedule with obligations in 2023–2026 indicate widening geographic reach and growing access to federal buyers. These moves suggest channels are being added beyond existing commercial accounts.

Innovation-Driven Growth: Emphasis on Agentic AI consulting and conversational‑AI offerings, alongside an AI/ML focus and a 100+ person offshore development center, points to investment in newer, in‑demand service lines. This positioning aligns the portfolio with current AI‑led project demand.

Strong Hiring & Retention: Frequent hiring posts across roles and locations suggest ongoing demand and added delivery capacity. Public headcount bands around 101–250 and a highlighted 100+ person India ODC reinforce the picture of an actively scaling team.